Across TCGA pan-cancer cohorts, SF3A1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SF3A1 data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SF3A1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SF3A1 expression acts as an unfavorable survival marker.
HNSC, LUSC, and ESCA are the cancer types where SF3A1 Mutation most reproducibly stratifies survival.